Publications: Dr John Riches
Hayama M, Riches JC
(
2024
)
.
Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic Leukemia
.
OncoTargets and Therapy
vol.
17
,
181
-
198
.
D’Avola A, Legrave N, Tajan M, Chakravarty P, Shearer RL, King HW, Kluckova K, Cheung EC et al.
(
2024
)
.
PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma
.
Journal of Clinical Investigation
vol.
134
,
(
4
)
D’Avola A, Kluckova K, Finch AJ, Riches JC
(
2023
)
.
Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers
.
OncoTargets and Therapy
vol.
16
,
371
-
383
.
Eyre TA, Riches JC
(
2023
)
.
The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives
.
Cancers
vol.
15
,
(
9
)
Tausch E, Malcikova J, Riches JC, Edelmann J
(
2023
)
.
Editorial: Biology and treatment of high-risk CLL
.
Frontiers in Oncology
vol.
12
,
Edelmann J, Malcikova J, Riches JC
(
2023
)
.
Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?
.
Frontiers in Oncology
vol.
13
,
Kluckova K, D'Avola A, Riches JC
(
2022
)
.
Advances in Understanding of Metabolism of B-Cell Lymphoma: Implications for Therapy
.
Cancers
vol.
14
,
(
22
)
Keogh RJ, Riches JC
(
2022
)
.
The Use of Breath Analysis in the Management of Lung Cancer: Is It Ready for Primetime?
.
Current Oncology
vol.
29
,
(
10
)
7355
-
7378
.
Bradwell S, Hone L, Thorneycroft K, Lambourne J, Aries JA, Davies JK, Cutino-Moguel T, Riches JC
(
2022
)
.
2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients
.
Leukemia Research
vol.
119
,
Kluckova K, Clear AJ, D'Avola A, Rassenti LZ, Kipps TJ, Gribben JG, Riches JC
(
2022
)
.
B‐cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities
.
HemaSphere
vol.
6
,
(
6
)
D'Avola A, Legrave N, Tajan M, Chakravarty P, Shearer RL, King HW, Kluckova K, Cheung EC et al.
(
2022
)
.
PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma
.
Journal of Clinical Investigation
vol.
132
,
(
9
)
Walewska R, Parry‐Jones N, Eyre TA, Follows G, Martinez‐Calle N, McCarthy H, Parry H, Patten PEM et al.
(
2022
)
.
Guideline for the treatment of chronic lymphocytic leukaemia
.
British Journal of Haematology
vol.
197
,
(
5
)
544
-
557
.
Caldwell L, Bapat A, Drumright L, Lambourne J, Jimenez-England F, Aries J, Eccersley L, Hallam S et al.
(
2021
)
.
Cessation of ciprofloxacin prophylaxis in haemato-oncology patients
.
Clin Infect Dis
Ali JK, Riches JC
(
2021
)
.
The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials
.
Cancers
vol.
13
,
(
23
)
D'Avola A, Legrave N, Tajan M, Chakravarty P, Shearer R, King H, Cheung E, Clear AJ et al.
(
2021
)
.
Phosphoglycerate Dehydrogenase Is Required for Germinal Center Formation and Is a Therapeutic Target in MYC- driven Lymphoma
.
Blood
vol.
138
,
(
Supplement 1
)
717
-
717
.
Eyre TA, Riches JC, Patten PEM, Walewska R, Marr H, Follows G, Hillmen P, Schuh AH et al.
(
2021
)
.
Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper
.
British Journal of Haematology
vol.
196
,
(
4
)
864
-
870
.
Vijenthira A, Gong I, Fox TA, Booth S, Cook G, Fattizzo B, Moro FM, Razanamahery J et al.
(
2021
)
.
Outcomes of Adult and Pediatric Patients with Hematologic Malignancies and COVID-19: A Systematic Review and Meta-Analysis of 1847 Patients
.
Blood
vol.
136
,
(
Supplement 1
)
39
-
41
.
Riches JC
(
2021
)
.
Impact of COVID-19 in patients with lymphoid malignancies
.
World Journal of Virology
vol.
10
,
(
3
)
97
-
110
.
King HW, Orban N, Riches JC, Clear AJ, Warnes G, Teichmann SA, James LK
(
2021
)
.
Single-cell analysis of human B cell maturation predicts how antibody class switching shapes selection dynamics
.
Science Immunology
vol.
6
,
(
56
)
Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, Martín-Moro F, Razanamahery J et al.
(
2020
)
.
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
.
Blood
vol.
136
,
(
25
)
2881
-
2892
.
Aries JA, Davies JK, Auer RL, Hallam SL, Montoto S, Smith M, Sevillano B, Foggo V et al.
(
2020
)
.
Clinical Outcome of Coronavirus Disease 2019 in Haemato-oncology Patients
.
British Journal of Haematology
King HW, Orban N, Riches JC, Clear AJ, Warnes G, Teichmann SA, James LK
(
2020
)
.
Antibody repertoire and gene expression dynamics of diverse human B cell states during affinity maturation
.
Clear AJ, D'Avola A, Agrawal SG, Rassenti LZ, Kipps TJ, Gribben JG, Riches J
(
2018
)
.
B-Cell Receptor Signaling Drives Glycolysis in Chronic Lymphocytic Leukemia Cells
.
Blood
.
vol.
132
,
Riches JC, Gribben JG
(
2016
)
.
Mechanistic and clinical aspects of lenalidomide treatment for chronic lymphocytic leukemia
.
Current Cancer Drug Targets
vol.
16
,
McClanahan F, Riches JC, Miller S, Day WP, Kotsiou E, Neuberg D, Croce CM, Capasso M et al.
(
2015
)
.
Mechanisms of PD-L1/PD-1–mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model
.
Blood
vol.
126
,
(
2
)
212
-
221
.
Riches JC, Gribben JG
(
2014
)
.
Immunomodulation and Immune Reconstitution in Chronic Lymphocytic Leukemia
.
Seminars in Hematology
vol.
51
,
(
3
)
228
-
234
.
Riches JC, O'Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Werner L, Croce CM et al.
(
2014
)
.
Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations
.
Blood
.
vol.
123
,
4101
-
4110
.
Riches JC, Gribben JG
(
2014
)
.
Hanging tough: CMV-specific CD8+ T cells in CLL
.
Blood
vol.
123
,
(
5
)
608
-
609
.
McClanahan F, Riches JC, Miller S, Ghazaly E, Day W, Capasso M, Gribben J
(
2014
)
.
PD-1/PD-L1 mediated T-cell dysfunction in CLL is not absolute and can be at least partially reversed in vivo by the immune-modulatory drug lenalidomide
.
ONCOLOGY RESEARCH AND TREATMENT
vol.
37
,
236
-
236
.
Riches JC, O'Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Werner L, Croce CM et al.
(
2014
)
.
Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by <i>NOTCH1</i> mutations
.
BLOOD
vol.
123
,
(
26
)
4101
-
4110
.
Riches JC, Gribben JG
(
2013
)
.
Advances in chimeric antigen receptor immunotherapy for chronic lymphocytic leukemia
.
Discov Med
vol.
16
,
(
90
)
295
-
302
.
Chen S-S, Herndon TM, Emson C, Riches JC, McClanahan F, Tong T, Yan X-J, Patten PEM et al.
(
2013
)
.
Intraclonal Complexity Of CLL Fractions In Cell Proliferation Rates, Gene Expression Signatures, and Responses To Autologous T-Cell Help In Peripheral blood and Secondary Lymphoid Tissues
.
Blood
.
vol.
122
,
Riches JC, Sangaralingam A, Chaplin T, McClanahan F, Iqbal S, Agrawal SG, Ramsay AG, Gribben J
(
2013
)
.
NK Cells From CLL Patients Exhibit Down-Regulation Of Interferon Response Genes That Can Be Reversed With Lenalidomide
.
Blood
vol.
122
,
(
21
)
McClanahan F, Miller S, Riches JC, Ghazaly E, Day WP, Capasso M, Gribben J
(
2013
)
.
T-Cell Dysfunction In CLL Is Mediated Not Only By PD-1/PD-L1 But Also By PD-1/PD-L2 Interactions - Partial Functionality Is Maintained In PD-1 Defined CD8 Subsets and This Can Be Further Promoted By Ibrutinib Treatment
.
Blood
vol.
122
,
(
21
)
O'Donovan CJ, Ramsay AG, McClanahan F, Rassenti L, Kipps TJ, Gribben J, Riches JC
(
2013
)
.
Trisomy 12 CLL Cells Have High Surface Expression Of Integrins Involved In Lymphocyte Trafficking But This Does Not Translate Into Improved LFA-1-Mediated Motility
.
Blood
vol.
122
,
(
21
)
Ene-Obong A, Clear AJ, Watt J, Wang J, Fatah R, Riches JC, Marshall JF, Chin-Aleong J et al.
(
2013
)
.
Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma
.
Gastroenterology
vol.
145
,
(
5
)
1121
-
1132
.
Riches JC, Gribben JG
(
2013
)
.
Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications
.
Hematol Oncol Clin North Am
vol.
27
,
(
2
)
207
-
235
.
Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG, Gribben JG
(
2013
)
.
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production
.
Blood
vol.
121
,
(
9
)
1612
-
1621
.
Gribben JG, Riches JC
(
2013
)
.
Immunotherapeutic strategies including transplantation: eradication of disease
.
Hematology Am Soc Hematol Educ Program
vol.
2013
,
151
-
157
.
Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG, Gribben JG
(
2012
)
.
Characterizing Immunophenotypic and Functional Pseudo-Exhaustion in T Cells From CLL Patients: The Impact of Lenalidomide
.
Blood
vol.
120
,
(
21
)
Riches JC, Gribben JG
(
2012
)
.
Less expensive CARs?
.
Cytotherapy
vol.
14
,
(
7
)
773
-
774
.
Riches JC, Ramsay AG, Gribben JG
(
2012
)
.
Immune reconstitution in chronic lymphocytic leukemia
.
Curr Hematol Malig Rep
vol.
7
,
(
1
)
13
-
20
.
Riches JC, Ramsay AG, Gribben JG
(
2012
)
.
Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy
.
Curr Pharm Des
vol.
18
,
(
23
)
3389
-
3398
.
McClanahan F, Ghirelli C, Greaves P, Riches JC, Coutinho R, Ramsay AG, Gribben JG
(
2012
)
.
Inhibitory Ligands CD200, CD270, CD274 and CD276 Are Expressed On Eμ-TCL1 Transgenic Mouse Splenocytes and Are of Potential Relevance to Impaired T-Cell Function in Vivo
.
BLOOD
.
vol.
120
,
Riches JC, Sangaralingam A, Kiaii S, Chaplin T, Cekdemir D, Iqbal S, Ramsay AG, Gribben JG
(
2011
)
.
Impact of Lenalidomide on Gene Expression Profiles of Malignant and Immune Cells in Patients with Chronic Lymphocytic Leukemia
.
Blood
vol.
118
,
(
21
)
Riches JC, Davies J, Iqbal S, Fatah R, Agrawal S, Ramsay AG, Gribben JG
(
2011
)
.
T-Cells From Patients with CLL Exhibit Phenotypic and Transcription Factor Profiles of Exhaustion Independent of CMV Serostatus
.
Blood
vol.
118
,
(
21
)
Riches JC, Ramsay AG, Gribben JG
(
2011
)
.
Chronic lymphocytic leukemia: an update on biology and treatment
.
Curr Oncol Rep
vol.
13
,
(
5
)
379
-
385
.
Riches JC, Sangaralingam A, Kiaii S, Chaplin T, Cekdemir D, Iqbal S, Ramsay AG, Gribben JG
(
2011
)
.
Impact of Lenalidomide on Gene Expression Profiles of Malignant and Immune Cells in Patients with Chronic Lymphocytic Leukemia
.
BLOOD
.
vol.
118
,
446
-
446
.
Riches JC, Davies J, Iqbal S, Fatah R, Agrawal S, Ramsay AG, Gribben JG
(
2011
)
.
T-cells from Patients With CLL Exhibit Phenotypic and Transcription Factor Profiles Of Exhaustion Independent of CMV Serostatus
.
Blood
.
vol.
118
,
1780
-
1783
.
Riches JC, Ramsay AG, Gribben JG
(
2010
)
.
T-cell function in chronic lymphocytic leukaemia
.
Semin Cancer Biol
vol.
20
,
(
6
)
431
-
438
.
Riches JC, Gribben JG
(
2009
)
.
Interesting times in the diagnosis and treatment of CLL
.
Oncology (Williston Park)
vol.
23
,
(
12
)
1043
-
1046
.
Bain BJ, Riches J
(
2009
)
.
Help with HELLP
.
American Journal of Hematology
vol.
85
,
(
1
)
70
-
70
.
Riches J, Naresh K, Reid A, Macdonald D
(
2009
)
.
Burkitt lymphoma following renal transplantation
.
British Journal of Haematology
vol.
146
,
(
6
)
583
-
583
.